Good morning :)
Place Order
Add to Watchlist

Hester Biosciences Ltd

HESTERBIO Share Price

1,833.900.52% (-9.60)
High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP

With a market cap of ₹1,568 cr, stock is ranked 1,220

Stock is 3.70x as volatile as Nifty

HESTERBIO Stock Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Avg

The stock has a moderate number of red flags

How to use scorecard? Learn more

With a market cap of ₹1,568 cr, stock is ranked 1,220

Stock is 3.70x as volatile as Nifty

HESTERBIO Performance & Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
57.075.180.38%
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
44.826.380.56%

HESTERBIO Analyst Ratings & Forecast

Analyst Ratings data is currently unavailable for this stock

Price Upside

Earnings Growth

Rev. Growth

HESTERBIO Company Profile

Hester Biosciences Limited is engaged in manufacturing of poultry vaccines and large animal vaccines, and trading of poultry health products and large animal health products. Its segments include Poultry Division and Large Animal Division.

HESTERBIO Similar Stocks (Peers)

Compare with peers 
PE Ratio
40.39
1Y Return
11.05%
Buy Reco %
75.00
PE Ratio
-1,038.02
1Y Return
4.73%
Buy Reco %
100.00
PE Ratio
91.78
1Y Return
2.04%
Buy Reco %
66.67
PE Ratio
-2,782.98
1Y Return
300.90%
Buy Reco %
PE Ratio
45.45
1Y Return
106.46%
Buy Reco %
Compare with Peers
HESTERBIO Sentiment Analysis
New
Crisp summary & key insights to decode earnings calls instantly

HESTERBIO Stock Summary · February 2025

In Q3 FY25, the company faced significant challenges, including a 6% decline in divisional product sales and a 24% drop in the Animal Healthcare System, largely due to external pressures like lower milk prices and regulatory bans. However, an impressive 85% year-on-year profit increase for the first nine months was driven by operational efficiencies and foreign exchange gains. The Petcare division thrived with a 105% sales surge, reflecting strong market potential, while the Poultry Healthcare segment benefited from heightened disease awareness. Despite a dip in consolidated EBITDA, management remains optimistic about long-term growth, particularly in the Petcare sector, and is committed to innovation and strategic expansion, especially in the African market.

Key Points on Hesterbio Stock
HESTERBIO Stock Growth Drivers
7
  • Strong Financial Performance

    Hester Biosciences Limited has reported significant financial achievements, including a year-on-year profitability growth of 85%

  • Growth in Poultry Healthcare Division

    The Poultry Healthcare division has shown strong performance, with sales increasing by 12% in Q3

HESTERBIO Stock Challenges
4
  • Decline in Financial Performance

    Hester Biosciences reported disappointing financial results, with a consolidated EBITDA of Rs. 5 crore, the

  • Sales Decline in Key Divisions

    The Animal Healthcare System experienced a 24% decline in sales for Q3, although it maintained

HESTERBIO Forecasts

HESTERBIO Forecast

empty forecast

Forecast data is currently unavailable

Forecast data is currently unavailable

Price

Price Upside

Revenue

Revenue Growth

Earnings

Earnings Per Share

HESTERBIO

Income

Balance Sheet

Cash Flow

HESTERBIO Income Statement

Industry refers to the sub-sector this company belongs to.
Lower than Industry Revenue Growth
A higher-than-industry revenue growth represents increased potential for the company to increase their market share

Over the last 5 years, revenue has grown at a yearly rate of 11.53%, vs industry avg of 19.04%

Decreasing Market Share
Market share is the percentage of an industry's total sales going to a particular company. It gives a general idea of the size of a company v/s its competitors

Over the last 5 years, market share decreased from 2.42% to 1.73%

Lower than Industry Net Income
Net income is equal to net earnings (profit) less expenses. This number is an important measure of how profitable the company is

Over the last 5 years, net income has grown at a yearly rate of -14.6%, vs industry avg of 2.04%

Loading...

Financial YearFY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Total Revenue123.53138.49185.28189.64219.01249.17285.65319.80319.13319.13
Raw Materialssubtract29.1135.3941.9244.1546.6375.4182.7487.14250.05250.05
Power & Fuel Costsubtract5.596.377.838.137.5710.2812.7415.30
Employee Costsubtract18.3223.2428.9340.6538.9245.3356.0264.13
Selling & Administrative Expensessubtract15.9317.9224.9937.7835.4740.1854.7756.48
Operating & Other expensessubtract13.155.756.36-2.8520.413.829.2227.85
Depreciation/Amortizationsubtract7.009.6611.7613.0713.3116.5820.7017.1716.8016.80
Interest & Other Itemssubtract3.504.046.637.376.604.069.3219.7812.7012.71
Taxes & Other Itemssubtract7.3810.5115.2912.1615.6814.1713.5313.0712.0812.09
EPS27.6830.1148.8734.3040.4646.2531.2822.1933.8932.30
DPS5.3010.0011.006.6010.0010.008.006.007.006.00
Payout ratio0.190.330.230.190.250.220.260.270.210.19

HESTERBIO Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

HESTERBIO Past Performance & Peer Comparison

Comparing 3 stocks from 
Health CareBiotechnology

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Hester Biosciences Ltd57.035.180.38%
Biocon Ltd40.391.620.37%
Onesource Specialty Pharma Ltd-1,038.0247.11
Sai Life Sciences Ltd91.7816.01

HESTERBIO Stock Price Comparison

Compare HESTERBIO with any stock or ETF
Compare HESTERBIO with any stock or ETF
HESTERBIO
Loading...

HESTERBIO Shareholdings

HESTERBIO Promoter Holdings Trend

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

HESTERBIO Institutional Holdings Trend

Total Retail Holding
Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding
Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

HESTERBIO Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding53.73%0.00%0.02%0.87%45.38%

Jun 2024

Sep 2024

Dec 2024

Mar 2025

HESTERBIO Shareholding History

Dec '23MarJunSepDec '24Mar0.43%0.43%0.52%0.61%0.59%0.87%

Mutual Funds Invested in HESTERBIO

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 1 Mutual Funds holding Hester Biosciences Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
0.0006%0.05%0.00%94/109 (-6)

Compare 3-month MF holding change on Screener

HESTERBIO Insider Trades & Bulk Stock Deals

Hmm, looks like there hasn't been any net deal activity in the last 6 months

smallcases containing HESTERBIO stock

Looks like this stock is not in any smallcase yet.

HESTERBIO Events

HESTERBIO Dividend Trend

No Trend In Dividends
Dividends are the portion of earnings that a company distributes to all its shareholders every year

HESTERBIO has shown inconsistent dividend trend over the last 5 years

Dividend Yield
Dividend return is one of the most important things to be considered while investing for long term. It is the additional return on top of what investors earn through price appreciation

Current dividend yield is 0.38%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹3.80 every year

Dividends

Corp. Actions

Announcements

Legal Orders

HESTERBIO Upcoming Dividends

No upcoming dividends are available

HESTERBIO Past Dividends

Cash Dividend

Ex DateEx DateAug 22, 2024

Final
Final | Div/Share: ₹6.00

Dividend/Share

6.00

Ex DateEx Date

Aug 22, 2024

Cash Dividend

Ex DateEx DateSep 13, 2023

Final
Final | Div/Share: ₹8.00

Dividend/Share

8.00

Ex DateEx Date

Sep 13, 2023

Cash Dividend

Ex DateEx DateAug 11, 2022

Final
Final | Div/Share: ₹10.00

Dividend/Share

10.00

Ex DateEx Date

Aug 11, 2022

Cash Dividend

Ex DateEx DateAug 5, 2021

Final
Final | Div/Share: ₹10.00

Dividend/Share

10.00

Ex DateEx Date

Aug 5, 2021

Cash Dividend

Ex DateEx DateAug 27, 2020

Final
Final | Div/Share: ₹6.60

Dividend/Share

6.60

Ex DateEx Date

Aug 27, 2020

HESTERBIO Stock News & Opinions

Spotlight
Hester Biosciences registers 30% YoY jump in Q4 PAT PAT to Rs 9.6 crore

The Animal Division, which includes both Ruminants and Pet health products, reported an 8% growth in revenue to Rs 30.53 crore in Q4 FY25. The Poultry Healthcare division's revenue grew by 3% YoY to Rs 46.08 crore during the period under review. While EBITDA expanded by 8% YoY to Rs 14.76 crore, EBITDA margin remained constant at 19%. On a consolidated basis, the company has recorded 76% drop in net profit to Rs 1.54 crore even as a revenues increased by 3% to Rs 81.92 crore in Q4 FY25 over Q4 FY24. For FY25, Hester Bio has registered a net profit of Rs 28.82 crore (up 36% YoY) and revenue from operations of Rs 304.54 crore (up 2% YoY). In its outlook, the company said that it remains focused on deepening its presence across all core segments while maintaining strong operational discipline. The company is on track to launch the Avian Influenza vaccine and expand its portfolio of feed supplements and disinfectants in the Poultry Healthcare Division, creating new domestic and export opportunities. In the Animal Division, efforts will be on broadening the nutritional and therapeutic product range to meet evolving market needs and strengthen market share. Continued investments in product development, supply chain efficiency, and customer engagement will drive sustainable growth. Hester is also prioritising international expansion, with a strong focus on scaling its Africa operations and strengthening its presence in existing and new geographies, aligned with its long-term vision of global leadership in animal healthcare,' the company stated. Hester Biosciences Limited is one of the India's leading animal health company, manufacturing vaccines and health products. It is the second largest poultry vaccine manufacturer, with approximately 35% market share in India. The scrip slipped 3.20% to currently trade at Rs 1643.50 on the BSE. Powered by Capital Market - Live

1 week agoCapital Market - Live
Earnings
Hester Biosciences consolidated net profit declines 73.94% in the March 2025 quarter

Net profit of Hester Biosciences declined 73.94% to Rs 1.29 crore in the quarter ended March 2025 as against Rs 4.95 crore during the previous quarter ended March 2024. Sales rose 3.37% to Rs 81.93 crore in the quarter ended March 2025 as against Rs 79.26 crore during the previous quarter ended March 2024. For the full year,net profit rose 45.53% to Rs 27.49 crore in the year ended March 2025 as against Rs 18.89 crore during the previous year ended March 2024. Sales rose 2.15% to Rs 311.10 crore in the year ended March 2025 as against Rs 304.55 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales81.9379.26 3 311.10304.55 2 OPM %23.4120.09 -19.6317.62 - PBDT7.9213.61 -42 56.3749.13 15 PBT3.759.87 -62 39.5731.95 24 NP1.294.95 -74 27.4918.89 46 Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Board of Hester Biosciences recommends final dividend

Hester Biosciences announced that the Board of Directors of the Company at its meeting held on 9 May 2025, inter alia, have recommended the final dividend of Rs 7 per equity Share (i.e. 70%) , subject to the approval of the shareholders.Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Hester Biosciences to conduct board meeting

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 9 May 2025.Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Earnings
Hester Biosciences consolidated net profit rises 192.96% in the December 2024 quarter

Net profit of Hester Biosciences rose 192.96% to Rs 11.66 crore in the quarter ended December 2024 as against Rs 3.98 crore during the previous quarter ended December 2023. Sales declined 5.61% to Rs 63.22 crore in the quarter ended December 2024 as against Rs 66.98 crore during the previous quarter ended December 2023. ParticularsQuarter EndedDec. 2024Dec. 2023% Var. Sales63.2266.98 -6 OPM %8.0215.15 - PBDT17.6610.16 74 PBT13.376.41 109 NP11.663.98 193 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Hester Biosciences to declare Quarterly Result

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 30 January 2025.Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Hester Biosciences receives reaffirmation in credit rating for bank facilities

Hester Biosciences has received reaffirmation in credit ratings for bank facilities at CARE BBB+; Stable / CARE A2 from CARE Ratings. Powered by Capital Market - Live

4 months agoCapital Market - Live
Earnings
Hester Biosciences consolidated net profit rises 100.49% in the September 2024 quarter

Net profit of Hester Biosciences rose 100.49% to Rs 8.20 crore in the quarter ended September 2024 as against Rs 4.09 crore during the previous quarter ended September 2023. Sales rose 18.78% to Rs 83.69 crore in the quarter ended September 2024 as against Rs 70.46 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales83.6970.46 19 OPM %22.8918.75 - PBDT16.0711.05 45 PBT11.876.76 76 NP8.204.09 100 Powered by Capital Market - Live

6 months agoCapital Market - Live
Corporate
Hester Biosciences announces board meeting date

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 28 October 2024.Powered by Capital Market - Live

6 months agoCapital Market - Live
Earnings
Hester Biosciences consolidated net profit rises 8.01% in the June 2024 quarter

Net profit of Hester Biosciences rose 8.01% to Rs 6.34 crore in the quarter ended June 2024 as against Rs 5.87 crore during the previous quarter ended June 2023. Sales declined 6.35% to Rs 82.27 crore in the quarter ended June 2024 as against Rs 87.85 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales82.2787.85 -6 OPM %21.4516.35 - PBDT14.7314.31 3 PBT10.598.91 19 NP6.345.87 8 Powered by Capital Market - Live

9 months agoCapital Market - Live

Frequently asked questions

  1. What is the share price of Hester Biosciences Ltd (HESTERBIO) today?

    The share price of HESTERBIO as on 20th May 2025 is ₹1833.90. The stock prices are volatile and keep changing through the day depending upon various factors and market conditions.

  2. What is the return on Hester Biosciences Ltd (HESTERBIO) share?

    The past returns of Hester Biosciences Ltd (HESTERBIO) share are
    • Past 1 week: 8.28%
    • Past 1 month: 2.09%
    • Past 3 months: 14.87%
    • Past 6 months: -24.36%
    • Past 1 year: 5.52%
    • Past 3 years: -20.86%
    • Past 5 years: 65.19%

  3. What are the peers or stocks similar to Hester Biosciences Ltd (HESTERBIO)?

    The peers or stocks similar to Hester Biosciences Ltd (HESTERBIO) include:

  4. What is the dividend yield % of Hester Biosciences Ltd (HESTERBIO) share?

    The current dividend yield of Hester Biosciences Ltd (HESTERBIO) is 0.38.

  5. What is the market cap of Hester Biosciences Ltd (HESTERBIO) share?

    Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Hester Biosciences Ltd (HESTERBIO) is ₹1568.24 Cr as of 20th May 2025.

  6. What is the 52 week high and low of Hester Biosciences Ltd (HESTERBIO) share?

    The 52-week high of Hester Biosciences Ltd (HESTERBIO) is ₹3379 and the 52-week low is ₹1242.95.

  7. What is the PE and PB ratio of Hester Biosciences Ltd (HESTERBIO) stock?

    The P/E (price-to-earnings) ratio of Hester Biosciences Ltd (HESTERBIO) is 57.03. The P/B (price-to-book) ratio is 5.18.

  8. Which sector does Hester Biosciences Ltd (HESTERBIO) belong to?

    Hester Biosciences Ltd (HESTERBIO) belongs to the Health Care sector & Biotechnology sub-sector.

  9. How to buy Hester Biosciences Ltd (HESTERBIO) shares?

    You can directly buy Hester Biosciences Ltd (HESTERBIO) shares on Tickertape. Simply sign up, connect your demat account and place your order.